Glenmark Pharmaceuticals receives tentative ANDA approval for Solifenacin Succinate Tablets

From USFDA

Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Solifenacin Succinate Tablets, 5 mg and 10 mg, the generic version of Vesicare Tablets, 5 mg and 10 mg of Astellas Pharma US Inc.

According to IMS Health sales data for the 12 month period ending April 2017, the Vesicare Tablets, 5 mg and 10 mg market achieved annual sales of approximately $1.1 billion.

Powered by Capital Market - Live News